The German Cancer Consortium (DKTK) multi-center prospective phase 1/2 68Ga-PSMA-11 PET-imaging trial in newly-diagnosed high-risk prostate cancer: Safety and diagnostic accuracy compared to histopathology and their impact on patient management.

Saved in:
Bibliographic Details
Title: The German Cancer Consortium (DKTK) multi-center prospective phase 1/2 68Ga-PSMA-11 PET-imaging trial in newly-diagnosed high-risk prostate cancer: Safety and diagnostic accuracy compared to histopathology and their impact on patient management.
Authors: Giesel FL; Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany.; Department of Nuclear Medicine, Medical Faculty and University Hospital Duesseldorf, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany.; Institute for Radiation Sciences, Osaka University, Osaka, Japan., Koerber SA; Department of Radiation Oncology, Barmherzige Brüder Hospital Regensburg, Regensburg, Germany.; Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany., Hadaschik B; Department of Urology, University Hospital Essen, Essen, Germany., Kiefer S; Institute for Surgical Pathology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg im Breisgau, Germany., Schwarzenboeck S; Department of Nuclear Medicine, University Medical Centre, Rostock, Germany., Rahbar K; Department of Nuclear Medicine, Münster University Hospital, Münster, Germany., Derlin T; Department of Nuclear Medicine, Hannover Medical School, Hanover, Germany., Grott CA; Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany., Heck M; Department of Urology, TUM University Hospital, School of Medicine and Health, Technical University Munich, Munich, Germany., Jilg C; Department of Urology, Faculty of Medicine, University of Freiburg-Medical Centre, Freiburg, Germany., Meyer PT; Department of Nuclear Medicine, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany., Ruf J; Department of Nuclear Medicine, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany., Schmidt K; ABX-CRO, Dresden, Germany., Kotzerke J; Department of Nuclear Medicine, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany., la Fougère C; Department of Nuclear Medicine and Clinical Molecular Imaging, University Hospital Tuebingen, Tuebingen, Germany., Reischl G; Department of Preclinical Imaging and Radiopharmacy, University Hospital Tuebingen, Tuebingen, Germany., Virgolini I; Department of Nuclear Medicine, University Hospital Innsbruck, Innsbruck, Austria., Herrmann K; Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, Essen, Germany.; Cancer Consortium partner site Essen/Düsseldorf, DKFZ and University Hospital Essen, Essen, Germany., Burger IA; Department of Nuclear Medicine, Kantonsspital Baden, Affiliated Hospital for Research and Teaching of the Faculty of Medicine of the University of Zurich, Baden, Switzerland.; Department of Nuclear Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland., Lorenzini T; Department of Nuclear Medicine, TUM University Hospital, School of Medicine and Health, Technical University Munich, Munich, Germany.; German Cancer Consortium (DKTK), Munich, Germany., Werner M; Institute for Surgical Pathology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg im Breisgau, Germany., Stenzinger A; Institute of Pathology, Division of Molecular Pathology, University Hospital Heidelberg, Heidelberg, Germany., Schwamborn K; Institute of Pathology, Technical University of Munich, School of Medicine, Munich, Germany., Radtke JP; Department of Urology, Medical Faculty, University Duesseldorf, Düsseldorf, Germany.; Department of Urology, University Hospital Essen, Essen, Germany., Hohenfellner M; Department of Urology, University Hospital Heidelberg and National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg, Germany., Debus J; Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany., Weber WA; Department of Nuclear Medicine, TUM University Hospital, School of Medicine and Health, Technical University Munich, Munich, Germany.; German Cancer Consortium (DKTK), Munich, Germany.; Center for Translational Cancer Research (TranslaTUM), Technical University of Munich, Munich, Germany.; Bavarian Cancer Research Center (BZKF), Munich, Germany., Haberkorn U; Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany., Kopka K; Division of Radiopharmaceutical Chemistry, German Cancer Research Center, Heidelberg, Germany.; Helmholtz-Zentrum Dresden-Rossendorf e.V., Institute of Radiopharmaceutical Cancer Research, Dresden, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany., Eiber M; Department of Nuclear Medicine, TUM University Hospital, School of Medicine and Health, Technical University Munich, Munich, Germany. matthias.eiber@tum.de.; German Cancer Consortium (DKTK), Munich, Germany. matthias.eiber@tum.de.; Bavarian Cancer Research Center (BZKF), Munich, Germany. matthias.eiber@tum.de.
Corporate Authors: 68Ga-PSMA-11 DKTK trial contributors
Source: European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2026 Apr; Vol. 53 (5), pp. 2994-3006. Date of Electronic Publication: 2025 Nov 15.
Publication Type: Journal Article; Multicenter Study; Clinical Trial, Phase II; Clinical Trial, Phase I; Comparative Study
Journal Info: Publisher: Springer-Verlag Berlin Country of Publication: Germany NLM ID: 101140988 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1619-7089 (Electronic) Linking ISSN: 16197070 NLM ISO Abbreviation: Eur J Nucl Med Mol Imaging Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1619-7089
DOI:10.1007/s00259-025-07540-4